EP1643973A1 - Preparations pharmaceutiques contenant du stearate de magnesium - Google Patents

Preparations pharmaceutiques contenant du stearate de magnesium

Info

Publication number
EP1643973A1
EP1643973A1 EP04740921A EP04740921A EP1643973A1 EP 1643973 A1 EP1643973 A1 EP 1643973A1 EP 04740921 A EP04740921 A EP 04740921A EP 04740921 A EP04740921 A EP 04740921A EP 1643973 A1 EP1643973 A1 EP 1643973A1
Authority
EP
European Patent Office
Prior art keywords
active ingredient
carrier
magnesium stearate
solid pharmaceutical
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04740921A
Other languages
German (de)
English (en)
Inventor
Michael John GlaxoSmithKline MONTEITH
Marian GlaxoSmithKline THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0316341.7A external-priority patent/GB0316341D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1643973A1 publication Critical patent/EP1643973A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Definitions

  • the present invention relates to solid pharmaceutical formulations which comprise an active ingredient drug substance, a carrier and magnesium stearate.
  • the invention also relates to the use of magnesium stearate to inhibit or reduce chemical reaction or degradation of an active ingredient substance in the presence of a carrier.
  • the invention also relates to the use of magnesium stearate for the stabilisation of an active ingredient drug substance in the presence of a carrier.
  • excipients which may be required as carriers, diluents, fillers, bulking agents, binders etc.
  • excipients are often used to give bulk to a pharmaceutical formulation where the active ingredient substance is present in very small quantities.
  • excipients are generally chemically inert. Over prolonged storage times, or under conditions of extreme heat or humidity, and in the presence of other materials, such inert substances can, however, undergo or participate in chemical degradation reactions.
  • Carrier substances that are commonly utilised in solid pharmaceutical formulations include reducing sugars, for example lactose, maltose and glucose. Lactose is particularly commonly used. It is generally regarded as an inert excipient.
  • Some inhalable dry powder pharmaceuticals are sensitive to moisture, as reported, for example in WO 00/28979 (SkyePharma AG).
  • the presence of moisture was found to interfere with the physical interaction between a carrier and a drug substance and thus with the effectiveness of drug delivery.
  • Such interference with physical interactions between a carrier and a drug substance is distinct from chemical instability resulting from degradation.
  • a commonly used excipient in solid pharmaceutical formulations is magnesium stearate, which is often included as a lubricant.
  • WO00/28979 (SkyePharma AG) describes the use of magnesium stearate in dry powder formulations for inhalation to improve resistance to moisture and to reduce the effect of penetrating moisture on the fine particle fraction (FPF) of an inhaled formulation.
  • WO00/53158 (Chiesi) describes a powder for use in a dry powder inhaler including an active ingredient and a carrier, wherein the carrier includes a lubricant, which may, for example, be inter alia magnesium stearate.
  • WO 96/23485 (Coordinated Drug Development Ltd), WO01/78694 and WO01/78695 (Vectura Limited) each describes a powder for use in a dry powder inhaler including an active ingredient particles and carrier particles, wherein the carrier includes an additive which is able to promote release of the active particles from the carrier particles.
  • Possible additive materials include amino acids, phospholipids, fatty acids and derivatives of fatty acids such as salts and esters, including inter alia magnesium stearate
  • the present invention provides the use of magnesium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein said active ingredient substance is susceptible to chemical interaction with said carrier.
  • the invention also provides the use of magnesium stearate to inhibit or reduce chemical degradation of an active ingredient substance in a solid pharmaceutical formulation comprising the active ingredient substance and a carrier, wherein said active ingredient substance is susceptible to chemical interaction with said carrier.
  • the chemical stability of the active substance in the formulation during long term storage may thereby be improved.
  • the present invention provides a solid pharmaceutical formulation comprising (a) an active ingredient substance susceptible to chemical interaction with a carrier, (b) a carrier and (c) magnesium stearate.
  • the present invention provides a method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, which comprises mixing magnesium stearate with said active ingredient substance and said carrier.
  • the invention also provides a method of inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, which method comprises mixing magnesium stearate with said active ingredient substance and said carrier.
  • compositions that have been prepared according to the present invention have greater chemical stability than the corresponding formulations without said ternary agent.
  • magnesium stearate may be referred to as a ternary agent.
  • 'Ternary agent' is used herein to mean a compound used in a formulation in addition to the active ingredient drug substance or substances (the 'primary' agent) and a bulk carrier material or materials (the 'secondary' agent). In some circumstances more than one ternary agent may be used. Optionally, further substances, possibly named 'quaternary agents', may also be present, for example as a lubricant. Any particular ternary or quaternary agent may have more than one effect.
  • the carrier is a reducing sugar, for example lactose, maltose or glucose (for example monohydrate glucose or anhydrate glucose). In a preferred embodiment, the carrier is lactose.
  • Alternative carriers include maltodextrin.
  • magnesium stearate present in a particular composition varies depending on the identity of the active ingredient drug substance present, the sizes of the particles and various other factors.
  • magnesium stearate is preferably present in an amount of from 0J to 20% w/w based on the total weight of the composition. More preferably the magnesium stearate is present in an amount of from 0.2 to 10% w/w based on the total weight of the composition. Still more preferably, the magnesium stearate is present in an amount of from 0.3 to 6% w/w, for example from 0.5 to 4% w/w.
  • the active ingredient substance is typically present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.
  • the active ingredient substance is present in an amount of from 0.02% to 10% w/w, more preferably in an amount of from 0.03 to 5%w/w, for example from 0.05% to 1% w/w, for example 0.1% w/w.
  • the active ingredient drug substance is one which includes a primary or secondary amine group.
  • the drug substance may contain the group Ar- CH(OH)-CH 2 -NH-R.
  • the group Ar may for example be selected from a group of formula (a) (b) (c) or (d):
  • R 12 represents hydrogen, halogen, -(CH 2 ) q OR 16 , -NR 6 C(O)R 17 , -NR 16 SO 2 R 17 , - SO 2 NR 16 R 17 , -NR 16 R 17 , -OC(O)R 18 or OC(O)NR 16 R 17
  • R 13 represents hydrogen, halogen or C 1- alkyl
  • R 12 represents -NHR 19 and R 13 and -NHR 19 together form a 5- or 6- membered heterocyclic ring;
  • R 14 represents hydrogen, halogen, -OR 16 or -NR 16 R 17 ;
  • R 15 represents hydrogen, halogen, halod. 4 alkyl, -OR 16 , -NR 16 R 17 , -OC(O)R 18 or OC(O)NR 16 R 17 ;
  • R 16 and R 17 each independently represents hydrogen or C 1- alkyl, or in the groups - NR 16 R 17 , -SO 2 NR 16 R 17 and -OC(O)NR 16 R 17 , R 16 and R 17 independently represent hydrogen or alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,
  • R 18 represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, d ⁇ alkyl, hydroxy, C- alkoxy or halo C ⁇ alkyl; and
  • q is zero or an integer from 1 to 4.
  • the group Ar is as defined above except that R 12 is not hydrogen.
  • preferred groups may be selected from the following groups (i) to (xxi):
  • Ar represents a group (i) as defined above.
  • Ar represents a group (iii) as defined above.
  • the group R preferably represents a moiety of formula:
  • A may represent (CH 2 ) m wherein m is an integer from 1 to 10; B may represent a heteroatom, e.g. oxygen, or a bond; C may represent (CH 2 ) n wherein n is an integer from 1 to 10; and D may represent an aryl group, e.g. an optionally substituted phenyl or pyridyl group.
  • Drug substances which may be formulated in accordance with the present invention include those described in International Patent Applications WO 02/066422,
  • Specific drug substances which may be formulated in accordance with the present invention include: 3-(4- ⁇ [6-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl ⁇ amino)hexyl] oxy ⁇ butyl) benzenesulfonamide for example as its cinnamate salt; 3-(3- ⁇ [7-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl ⁇ - amino)heptyl]oxy ⁇ propyl)benzenesulfonamide;
  • Other drug substances which may be formulated in accordance with the present invention include salmeterol, (R)-salmeterol, salbutamol, (R)-salbutamol, formoterol, (R,R)- formoterol, fenoterol, etanterol, naminterol, clenbuterol, pirbuterol, flerobuterol, reproterol, bambuterol and terbutaline and salts, solvates and other physiologically functional derivatives thereof.
  • the active ingredient drug substance may be in the form of a free acid or base or may be present as a salt, a solvate, or other physiologically functional derivative. Salts and solvates which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable.
  • Suitable salts for use in the invention include those formed with both organic and inorganic acids or bases.
  • Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, phenylacetic, substituted phenylacetic eg.
  • Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexyl amine and N-methyl- D-glucamine.
  • physiologically functional derivative of a drug substance may also be used in the invention.
  • physiologically functional derivative is meant a chemical derivative of a compound of having the same physiological function as the free compound, for example, by being convertible in the body thereto.
  • examples of physiologically functional derivatives include esters, for example compounds in which a hydroxyl group has been converted to a C h alky!, aryl, aryl C 1-6 alkyl, or amino acid ester.
  • the active ingredient drug substance is most preferably a selective long-acting ⁇ 2 - adrenoreceptor agonist.
  • Such compounds have use in the prophylaxis and treatment of a variety of clinical conditions, including diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
  • COPD chronic obstructive pulmonary diseases
  • rhinitis e.g. chronic and whez bronchitis, emphysema
  • respiratory tract infection e.g. rhinitis, including seasonal and allergic rhinitis.
  • Other conditions which may be treated include premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.
  • skin diseases e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases
  • conditions where lowering peptic acidity is desirable e.g. peptic and gastric ulceration
  • muscle wasting disease e.g. peptic and gastric ulceration
  • Formulations to which the present invention may be applied include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier and the magnesium stearate ternary agent as well as any other accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient, lactose, magnesium stearate and any other accessory ingredients, and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules.
  • the active ingredient drug substance may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include sterile powders, granules and tablets intended for dissolution immediately prior to administration.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose an acacia.
  • the invention finds particular application in dry powder compositions, in particular in dry powder compositions for topical delivery to the lung by inhalation.
  • Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
  • Packaging of the formulation may be suitable for unit dose or multi-dose delivery.
  • the formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715 or EP0237507).
  • An example of a unit-dose device is Rotahaler (see GB 2064336).
  • the Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing an active compound.
  • the strip is sufficiently flexible to be wound into a roll.
  • Medicaments for administration by inhalation desirably have a controlled particle size.
  • the optimum particle size for inhalation into the bronchial system is usually 1-1 O ⁇ m, preferably 2-5 ⁇ m (mass mean diameter, MMD). Particles having a size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
  • the particles of the active ingredient substance as produced may be size reduced by conventional means eg by micronisation.
  • the desired fraction may be separated out by air classification or sieving.
  • the particles will be crystalline.
  • the particle size of the carrier for example lactose, will be much greater than the drug substance within the present invention.
  • the carrier is lactose it will typically be present as milled lactose, for example with a mass mean diameter (MMD) of 60-90 ⁇ m and with not more than 15% having a particle diameter of less than 15 ⁇ m.
  • MMD mass mean diameter
  • the magnesium stearate will typically have a particle size in the range 1 to 50 ⁇ m, and more particularly 1 - 20 ⁇ m, e.g.1-1 O ⁇ m.
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the compounds and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example a beta- agonist may be used in combination with one or more other therapeutic agents selected from anti-inflammatory agents (for example a corticosteroid, or an NSAID,) anticholinergic agents (particularly an Mi, M 2 , M-
  • anti-inflammatory agents for example a corticosteroid, or an NSAID,
  • anticholinergic agents particularly an Mi, M 2 , M-
  • antiinfective agents e.g. antibiotics, antivirals
  • antihistamines e.g. antibiotics, antivirals
  • Suitable corticosteroids include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 - methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester, 6 ⁇ ,9 ⁇ - difluoro-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-17 ⁇ -propionyloxy- androsta-1 ,4-diene-17 ⁇ - carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester, beclomethasone esters (e.g.
  • the 17-propionate ester or the 17,21-dipropionate ester the 17-propionate ester or the 17,21-dipropionate ester
  • budesonide flunisolide
  • mometasone esters e.g. the furoate ester
  • triamcinolone acetonide e.g. the furoate ester
  • rofleponide triamcinolone acetonide
  • ciclesonide butixocort propionate
  • RPR-106541 the 17-propionate ester or the 17,21-dipropionate ester
  • ST-126 the 17-propionate ester or the 17,21-dipropionate ester
  • flunisolide e.g. the furoate ester
  • triamcinolone acetonide e.g. the furoate ester
  • rofleponide triamcinolone acetonide
  • ciclesonide butixocort propionate
  • Suitable NSAIDs include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists), cytokine antagonists (e.g. chemokine antagonists) or inhibitors of cytokine synthesis.
  • PDE phosphodiesterase
  • Suitable anticholinergic agents are those compounds that act as antagonists at the muscarinic receptor, in particular those compounds which are antagonists of the Mi and M 2 receptors.
  • exemplary compounds include the alkaloids of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines.
  • Preferred anticholinergics include ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e.g. as the bromide) and tiotropium (e.g. as the bromide) (CAS- 139404-48-1).
  • ipratropium e.g. as the bromide
  • oxitropium e.g. as the bromide
  • tiotropium e.g. as the bromide
  • Suitable antihistamines include any one or more of the numerous antagonists known which inhibit Hrreceptors, and are safe for human use. All are reversible, competitive inhibitors of the interaction of histamine with H receptors. Examples of preferred anti-histamines include methapyrilene and loratadine.
  • the invention further provides the use of an inhalable solid pharmaceutical formulation according to the invention for the manufacture of a medicament for the treatment of diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
  • COPD chronic obstructive pulmonary diseases
  • rhinitis including seasonal and allergic rhinitis.
  • the invention also provides a method for treating asthma, chronic obstructive pulmonary diseases (COPD), chronic or whez bronchitis, emphysema, respiratory tract infection upper respiratory tract, or rhinitis, including seasonal and allergic rhinitiscomprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation according to the invention.
  • COPD chronic obstructive pulmonary diseases
  • COPD chronic or whez bronchitis
  • emphysema emphysema
  • respiratory tract infection upper respiratory tract or rhinitis
  • rhinitis including seasonal and allergic rhinitiscomprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation according to the invention.
  • the invention provides a method of preparing a solid pharmaceutical preparation comprising combining in one or more steps: (a) an active ingredient substance susceptible to interaction with a carrier, (b) a carrier and (c) magnesium stearate.
  • Compound X was the cinnamate salt of 3-(4- ⁇ [6-( ⁇ (2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl ⁇ amino)hexyl]oxy ⁇ - butyl)benzene-sulfonamide.
  • the synthesis of compound X is described in Examples 45 and 46 in WO 02/066422.
  • Lactose monohydrate was obtained from Borculo Domo Ingredients as BP/USNF form. Before use, the Lactose Monohydrate was sieved through a coarse screen (mesh size 500 microns) to deaggregate the material. Compound X was micronised before use in an APTM icroniser to give a MMD (mean mass diameter) of from 2 to 5 microns.
  • Magnesium stearate was obtained from Peter Greven with MMD ⁇ 10 microns and used as supplied.
  • the magnesium stearate was combined with lactose monohydrate and blended using either a high shear mixer (a QMM, PMA or TRV series mixer) or a low shear tumbling blender (a Turbula mixer) to provide a ternary agent drug premix, hereinafter referred to as blend A.
  • Final blend B was obtained by first pre-mixing an appropriate quantity of blend A with compound X and then blending that blend A/compound X premix with further blend A in a weight ratio appropriate to provide blend B containing the magnesium stearate in the required quantity, as indicated in Table 1 and Tables 2 and 3 below.
  • the quantity of magnesium stearate in Tables 2 to 3 is the amount by weight of magnesium stearate present as a percentage of the total composition.
  • the final concentration of compound X in the blends was 0.1% w/w calculated on the basis of the weight of free base drug present.
  • the blended composition was transferred into blister strips or the type generally used for the supply of dry powder for inhalation and the blister strips were sealed in the customary fashion.
  • Table 1 The quantity of the various materials used in the various blends are shown in Table 1: Table 1
  • Detection was carried out by UV at 220nm with a HP1100 series detector model G1314A-VWD.
  • the area under the LC trace curve for the total impurities was compared with the total area under the curve, to give the %area/area figures given in Tables 2 and 3 .
  • Example 1 Comparison of compound X / lactose blends comprising magnesium stearate with controls
  • Example 2 Comparison of compound X / lactose blends comprising 0.5%, 1.0% and 2.0% magnesium stearate filled into blister strips with controls

Abstract

L'invention concerne l'utilisation de stéarate de magnésium dans l'inhibition ou la réduction d'interaction chimique entre une substance d'ingrédients actifs et un support dans une préparation pharmaceutique solide. Cette substance d'ingrédients actifs est sensible à l'interaction chimique avec le support. L'invention porte aussi sur une préparation pharmaceutique solide pouvant être inhalée contenant (a) une substance d'ingrédients actifs sensible à l'interaction chimique avec du lactose, (b) un support et (c) du stéarate de magnésium, et sur des utilisations de cette préparation et des procédés associés.
EP04740921A 2003-07-11 2004-07-08 Preparations pharmaceutiques contenant du stearate de magnesium Withdrawn EP1643973A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0316341.7A GB0316341D0 (en) 2003-07-11 2003-07-11 Pharmaceutical formulations
US50541503P 2003-09-23 2003-09-23
PCT/EP2004/007666 WO2005004845A1 (fr) 2003-07-11 2004-07-08 Preparations pharmaceutiques contenant du stearate de magnesium

Publications (1)

Publication Number Publication Date
EP1643973A1 true EP1643973A1 (fr) 2006-04-12

Family

ID=34066619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04740921A Withdrawn EP1643973A1 (fr) 2003-07-11 2004-07-08 Preparations pharmaceutiques contenant du stearate de magnesium

Country Status (3)

Country Link
EP (1) EP1643973A1 (fr)
JP (1) JP2009513529A (fr)
WO (1) WO2005004845A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
EP2279009A4 (fr) * 2008-05-05 2011-09-21 Univ Rochester Procédés et compositions pour le traitement ou la prévention d'une remodélisation cardiaque pathologique et d'une insuffisance cardiaque
PT2400950T (pt) 2009-02-26 2019-08-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(6-{2-[(2,6-diclorobenzil)oxi]ethoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011131663A1 (fr) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. Procédé de préparation de particules ayant des charges électrostatiques réduites
PL2621494T3 (pl) 2010-09-30 2019-04-30 Chiesi Farm Spa Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
LT2834244T (lt) * 2012-03-13 2016-11-10 Respivert Limited Kristalinės pi3 kinazės slopikliai
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
KR102410183B1 (ko) 2016-04-15 2022-06-17 치아타이 티안큉 파마수티컬 그룹 주식회사 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005213A1 (fr) * 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. Nouvelles compositions pharmaceutiques destinees a etre inhalees

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2216418T3 (es) 1995-12-07 2004-10-16 Jago Research Ag Boquilla para un inhalador para la administracion de varias dosis de un polvo seco farmacologico.
EP1131059B1 (fr) * 1998-11-13 2003-03-05 Jago Research Ag Poudre seche pour inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK1913939T3 (en) * 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005213A1 (fr) * 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. Nouvelles compositions pharmaceutiques destinees a etre inhalees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005004845A1 *

Also Published As

Publication number Publication date
JP2009513529A (ja) 2009-04-02
WO2005004845A1 (fr) 2005-01-20

Similar Documents

Publication Publication Date Title
US20100093866A1 (en) Pharmaceutical Formulations
AU2018282427B2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU8993501A (en) Novel tiotropium-containing inhalation powder
ZA200503692B (en) Powered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
WO2001078739A1 (fr) Combinaisons medicales comprenant du tiotropium et du propionate de fluticasone
WO2001078736A1 (fr) Combinaisons respiratoires a base de de tiotropium et de rofleponide
WO2001078745A1 (fr) Produits composes a usage medical renfermant du formoterol et de la mometasone et du proprionate de fluticasone
WO2010097115A1 (fr) Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
EP1646370A1 (fr) Formulations pharmaceutiques
EP1643973A1 (fr) Preparations pharmaceutiques contenant du stearate de magnesium
US20060165785A1 (en) Method of chemically stabilizing pharmaceutical formulations with cholesterol
US20140116434A1 (en) Dry Powder Inhaler Compositions
EP1427414A1 (fr) Compositions a inhaler comprenant des 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo(4,3-alpha)pyridines tricycliques
WO2006076222A2 (fr) Formulations pharmaceutiques
WO2005004846A1 (fr) Formulations pharmaceutiques inhalables contenant un ester de sucre
WO2001078744A1 (fr) Produits composes a usage medical renfermant du formoterol et de la mometasone
WO2001078742A1 (fr) Combinaison medicale comprenant du salmeterol et du budesonide
WO2010097114A1 (fr) Nouvelle combinaison d'agents thérapeutiques
WO2006066907A1 (fr) Formulations pharmaceutiques
US20060233716A1 (en) Pharmaceutical formulations
US20060210485A1 (en) Pharmaceutical formulations
EP1274436A1 (fr) Compositions medicales comprenant du (r,r)-formoterol et du rofleponide
WO2016057644A1 (fr) Stabilité améliorée de poudres sèches contenant du tiotropium et un acide aminé
EP2957550A1 (fr) Formulations pharmaceutiques comprenant du vilanterol
AU2002330687A1 (en) Inhalation compositions comprising tricyclis 5,6-dihydro-9H-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051207

Extension state: LT

Payment date: 20051207

Extension state: HR

Payment date: 20051207

17Q First examination report despatched

Effective date: 20070813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121024